Tokio Marine Asset Management Co. Ltd. Acquires 9,670 Shares of Pfizer Inc. (NYSE:PFE)

Tokio Marine Asset Management Co. Ltd. raised its holdings in Pfizer Inc. (NYSE:PFE) by 6.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 167,746 shares of the biopharmaceutical company’s stock after acquiring an additional 9,670 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Pfizer were worth $4,251,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 2.0%

PFE opened at $25.14 on Thursday. The stock has a market capitalization of $142.93 billion, a P/E ratio of 13.37, a P/E/G ratio of 0.88 and a beta of 0.52. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm’s fifty day simple moving average is $24.52 and its 200 day simple moving average is $24.47. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.60 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, July 25th. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. BMO Capital Markets reduced their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Redburn Atlantic reduced their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 30th. Wolfe Research lifted their price target on shares of Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.